REFERENCES
1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 2020;10:107-11.
2. Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019;26:25-32.
3. Riches-Suman K, Hussain A. Identifying and targeting the molecular signature of smooth muscle cells undergoing early vascular ageing. Biochim Biophys Acta Mol Basis Dis 2022;1868:166403.
4. Mack CP. Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2011;31:1495-505.
6. Beamish JA, He P, Kottke-Marchant K, Marchant RE. Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Eng Part B Rev 2010;16:467-91.
7. Christen T, Verin V, Bochaton-piallat M, et al. Mechanisms of neointima formation and remodeling in the porcine coronary artery. Circulation 2001;103:882-8.
8. Kocher O, Gabbiani F, Gabbiani G, et al. Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening. Biochemical and morphologic studies. Lab Invest 1991;65:459-70.
9. Cheng C, Seen D, Zheng C, Zeng R, Li E. Role of small GTPase RhoA in DNA damage response. Biomolecules 2021;11:212.
10. Ngo ATP, Parra-Izquierdo I, Aslan JE, McCarty OJT. Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and disease. Small GTPases 2021;12:440-57.
11. Tkach V, Bock E, Berezin V. The role of RhoA in the regulation of cell morphology and motility. Cell Motil Cytoskeleton 2005;61:21-33.
12. Solski PA, Helms W, Keely PJ, Su L, Der CJ. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ 2002;13:363-73.
13. Guan R, Xu X, Chen M, et al. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem 2013;70:613-22.
14. Loirand G, Scalbert E, Bril A, Pacaud P. Rho exchange factors in the cardiovascular system. Curr Opin Pharmacol 2008;8:174-80.
15. Loirand G, Rolli-Derkinderen M, Pacaud P. RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 2005;288:H1051-6.
16. Li M, Jiao Q, Xin W, et al. The emerging role of Rho guanine nucleotide exchange factors in cardiovascular disorders: insights into atherosclerosis: a mini review. Front Cardiovasc Med 2021;8:782098.
17. Yu L, Quinn DA, Garg HG, Hales CA. Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/Rho kinase/p27. Am J Respir Cell Mol Biol 2011;44:524-30.
18. Moon S. Rho GTPase-activating proteins in cell regulation. Trends in Cell Biology 2003;13:13-22.
19. Huang GH, Sun ZL, Li HJ, Feng DF. Rho GTPase-activating proteins: regulators of Rho GTPase activity in neuronal development and CNS diseases. Mol Cell Neurosci 2017;80:18-31.
20. Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. Biol Cell 2007;99:67-86.
21. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem 1999;274:32418-24.
22. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273:245-8.
23. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010;7:637-47.
24. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-98.
25. Garcia-Mata R, Boulter E, Burridge K. The “invisible hand”: regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol 2011;12:493-504.
26. Nagar H, Kim S, Lee I, et al. CRIF1 deficiency suppresses endothelial cell migration via upregulation of RhoGDI2. PLoS One 2021;16:e0256646.
27. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005;390:1-9.
28. Ahmad Mokhtar AMB, Ahmed SBM, Darling NJ, Harris M, Mott HR, Owen D. A complete survey of RhoGDI targets reveals novel interactions with atypical small GTPases. Biochemistry 2021;60:1533-51.
29. Riches-Suman K. Diverse roles of microRNA-145 in regulating smooth muscle (dys)function in health and disease. Biochem Soc Trans 2021;49:353-63.
30. Feng MB, Li GH, Dou FF. Long-chain non-coding RNA LOC554202 promotes proliferation, migration, and invasion of nasopharyngeal carcinoma cells by binding to microRNA-31 expression and regulating RhoA expression. Eur Rev Med Pharmacol Sci 2020;24:10550-6.
31. Korourian A, Roudi R, Shariftabrizi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med 2017;242:1842-7.
32. Wang BG, Li JS, Liu YF, Xu Q. MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839. Tumour Biol 2017;39:1010428317719577.
33. Wang H, Guo W, Jian Q, et al. MicroRNA-340 inhibits squamous cell carcinoma cell proliferation, migration and invasion by downregulating RhoA. J Dermatol Sci 2018;92:197-206.
34. Li Y, Ouyang M, Shan Z, et al. Involvement of microRNA-133a in the development of arteriosclerosis obliterans of the lower extremities via RhoA targeting. J Atheroscler Thromb 2015;22:424-32.
35. Liu L, Zang J, Chen X, et al. Role of miR-124 and miR-141 in the regulation of vascular reactivity and the relationship to RhoA and Rac1 after hemorrhage and hypoxia. Am J Physiol Heart Circ Physiol 2016;310:H206-16.
36. Chung DJ, Wu YL, Yang MY, Chan KC, Lee HJ, Wang CJ. Nelumbo nucifera leaf polyphenol extract and gallic acid inhibit TNF-α-induced vascular smooth muscle cell proliferation and migration involving the regulation of miR-21, miR-143 and miR-145. Food Funct 2020;11:8602-11.
37. Fujisawa K, Fujita A, Ishizaki T, Saito Y, Narumiya S. Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase. J Biol Chem 1996;271:23022-8.
38. Loirand G, Guérin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34.
39. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-93.
40. Mong PY, Wang Q. Activation of Rho kinase isoforms in lung endothelial cells during inflammation. J Immunol 2009;182:2385-94.
41. Cheng C, Liu XB, Xu DL, Zhang J. Increased ROCK1 not ROCK2 in circulating leukocytes in rats with myocardial ischemia/reperfusion. Perfusion 2020;35:819-25.
42. Chevrier V, Piel M, Collomb N, et al. The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol 2002;157:807-17.
43. van Nieuw Amerongen GP, van Hinsbergh VW. Cytoskeletal effects of Rho-like small guanine nucleotide-binding proteins in the vascular system. ATVB 2001;21:300-11.
44. Tojkander S, Gateva G, Lappalainen P. Actin stress fibers - assembly, dynamics and biological roles. J Cell Sci 2012;125:1855-64.
45. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999;285:895-8.
46. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-27.
47. Watanabe N, Madaule P, Reid T, et al. p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. EMBO J 1997;16:3044-56.
48. Saito K, Shiino T, Kurihara H, Harita Y, Hattori S, Ohta Y. Afadin regulates RhoA/Rho-associated protein kinase signaling to control formation of actin stress fibers in kidney podocytes. Cytoskeleton 2015;72:146-56.
49. Miralles F, Posern G, Zaromytidou A, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003;113:329-42.
50. Hill CS, Wynne J, Treisman R. The Rho family GTPases RhoA, Racl, and CDC42Hsregulate transcriptional activation by SRF. Cell 1995;81:1159-70.
51. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001;276:341-7.
52. Ai S, Kuzuya M, Koike T, et al. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways. Atherosclerosis 2001;155:321-7.
53. Qi Y, Liang X, Dai F, Guan H, Sun J, Yao W. RhoA/ROCK pathway activation is regulated by AT1 receptor and participates in smooth muscle migration and dedifferentiation via promoting actin cytoskeleton polymerization. Int J Mol Sci 2020;21:5398.
54. Pescatore LA, Bonatto D, Forti FL, Sadok A, Kovacic H, Laurindo FR. Protein disulfide isomerase is required for platelet-derived growth factor-induced vascular smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase activation. J Biol Chem 2012;287:29290-300.
55. Tang L, Dai F, Liu Y, et al. RhoA/ROCK signaling regulates smooth muscle phenotypic modulation and vascular remodeling via the JNK pathway and vimentin cytoskeleton. Pharmacol Res 2018;133:201-12.
56. Zhuge Y, Zhang J, Qian F, et al. Role of smooth muscle cells in cardiovascular disease. Int J Biol Sci 2020;16:2741-51.
57. Riches K, Franklin L, Maqbool A, et al. Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol 2013;45:1776-83.
58. Jain M, Chauhan AK. Role of integrins in modulating smooth muscle cell plasticity and vascular remodeling: from expression to therapeutic implications. Cells 2022;11:646.
59. Hayfron-Benjamin C, van den Born BJ, Maitland-van der Zee AH, et al. Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: the RODAM study. J Diabetes Complications 2019;33:572-8.
60. Khanam PA, Hoque S, Begum T, Habib SH, Latif ZA. Microvascular complications and their associated risk factors in type 2 diabetes mellitus. Diabetes Metab Syndr 2017;11 Suppl 2:S577-81.
61. Jin J, Wang X, Zhi X, Meng D. Epigenetic regulation in diabetic vascular complications. J Mol Endocrinol 2019;63:R103-15.
62. Contreras F, Rivera M, Vasquez J, De la Parte MA, Velasco M. Diabetes and hypertension physiopathology and therapeutics. J Hum Hypertens 2000;14 Suppl 1:S26-31.
63. DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9-16.
64. Ohri SK, Benedetto U, Luthra S, et al. Coronary artery bypass surgery in the UK, trends in activity and outcomes from a 15-year complete national series. Eur J Cardiothorac Surg 2022;61:449-56.
65. Spadaccio C, Benedetto U. Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease: quo vadis? Ann Cardiothorac Surg 2018;7:506-15.
66. d’Entremont MA, Yagi R, Salia SJS, et al. The effect of diabetes on surgical versus percutaneous left main revascularization outcomes: a systematic review and meta-analysis. J Cardiothorac Surg 2022;17:61.
67. Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 2018;391:939-48.
69. Raza S, Sabik JF 3rd, Ainkaran P, Blackstone EH. Coronary artery bypass grafting in diabetics: a growing health care cost crisis. J Thorac Cardiovasc Surg 2015;150:304-2.e2.
70. Royse A, Pamment W, Pawanis Z, et al. Patency of conduits in patients who received internal mammary artery, radial artery and saphenous vein grafts. BMC Cardiovasc Disord 2020;20:148.
71. Ak E, Ak K, Midi A, et al. Histopathologic evaluation of saphenous vein grafts in patients with type II diabetes mellitus undergoing coronary artery bypass grafting. Cardiovasc Pathol 2021;52:107328.
72. Martínez-González B, Reyes-Hernández CG, Quiroga-Garza A, et al. Conduits used in coronary artery bypass grafting: a review of morphological studies. Ann Thorac Cardiovasc Surg 2017;23:55-65.
73. Raza S, Blackstone EH, Houghtaling PL, et al. Influence of diabetes on long-term coronary artery bypass graft patency. J Am Coll Cardiol 2017;70:515-24.
74. Maltais S, Widmer RJ, Bell MR, et al. Reoperation for coronary artery bypass grafting surgery: outcomes and considerations for expanding interventional procedures. Ann Thorac Surg 2017;103:1886-92.
75. Sasaki Y, Suehiro S, Becker AE, Kinoshita H, Ueda M. Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. Heart 2000;83:69-75.
76. Kockx MM, Cambier BA, Bortier HE, De Meyer GR, Van Cauwelaert PA. The modulation of smooth muscle cell phenotype is an early event in human aorto-coronary saphenous vein grafts. Virchows Arch A Pathol Anat Histopathol 1992;420:155-62.
77. Davies MG, Hagen PO. Structural and functional consequences of bypass grafting with autologous vein. Cryobiology 1994;31:63-70.
78. Muto A, Model L, Ziegler K, Eghbalieh SD, Dardik A. Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. Circ J 2010;74:1501-12.
79. Ishiko K, Sakoda T, Akagami T, et al. Hyperglycemia induced cell growth and gene expression via the serum response element through RhoA and Rho-kinase in vascular smooth muscle cells. Prep Biochem Biotechnol 2010;40:139-51.
80. Chen GP, Zhang XQ, Wu T, Li L, Han J, Du CQ. Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process. J Diabetes Res 2015;2015:379287.
81. Hemmings KE, Riches-Suman K, Bailey MA, O’Regan DJ, Turner NA, Porter KE. Role of microRNA-145 in DNA damage signalling and senescence in vascular smooth muscle cells of type 2 diabetic patients. Cells 2021;10:919.
82. Madi HA, Riches K, Warburton P, O’Regan DJ, Turner NA, Porter KE. Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am J Physiol Cell Physiol 2009;297:C1307-17.
83. Riches K, Alshanwani AR, Warburton P, et al. Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol 2014;74:240-50.
84. Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE. Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: possible role of differential RhoA activity. Cardiovasc Revasc Med 2014;15:141-8.
85. Nagao T, Qin C, Grosheva I, Maxfield FR, Pierini LM. Elevated cholesterol levels in the plasma membranes of macrophages inhibit migration by disrupting RhoA regulation. Arterioscler Thromb Vasc Biol 2007;27:1596-602.
86. Wu W, Wang C, Zang H, et al. Mature vascular smooth muscle cells, but not endothelial cells, serve as the major cellular source of intimal hyperplasia in vein grafts. Arterioscler Thromb Vasc Biol 2020;40:1870-90.
87. McCallum JE, Mackenzie AE, Divorty N, et al. G-protein-coupled receptor 35 mediates human saphenous vein vascular smooth muscle cell migration and endothelial cell proliferation. J Vasc Res 2015;52:383-95.
88. Oliveira de Souza C, Sun X, Oh D. Metabolic functions of G protein-coupled receptors and β-arrestin-mediated signaling pathways in the pathophysiology of type 2 diabetes and obesity. Front Endocrinol 2021;12:715877.
89. Arnold C, Demirel E, Feldner A, et al. Hypertension-evoked RhoA activity in vascular smooth muscle cells requires RGS5. FASEB J 2018;32:2021-35.
90. Ivanova EA, Bobryshev YV, Orekhov AN. Intimal pericytes as the second line of immune defence in atherosclerosis. World J Cardiol 2015;7:583-93.
91. Lechartier B, Berrebeh N, Huertas A, Humbert M, Guignabert C, Tu L. Phenotypic diversity of vascular smooth muscle cells in pulmonary arterial hypertension: implications for therapy. Chest 2022;161:219-31.
92. Tsapara A, Luthert P, Greenwood J, Hill CS, Matter K, Balda MS. The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration. Mol Biol Cell 2010;21:860-70.
93. Qiao YC, Chen YL, Pan YH, et al. Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a PRISMA-compliant systematic review and meta-analysis. Medicine 2017;96:e6583.
94. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000;7:169-76.
95. Yang H, Chen XY, Kuang SJ, et al. Abnormal Ca2+ handling contributes to the impairment of aortic smooth muscle contractility in Zucker diabetic fatty rats. J Mol Cell Cardiol 2020;141:82-92.
97. Patel KK, Sehgal VS, Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. Eur J Pharmacol 2022;922:174906.
98. Bonetti P. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-48.
99. Ouyang QF, Han Y, Lin ZH, Xie H, Xu CS, Xie LD. Fluvastatin upregulates the α 1C subunit of CaV1.2 channel expression in vascular smooth muscle cells via RhoA and ERK/p38 MAPK pathways. Dis Markers 2014;2014:237067.
100. Kang S, Woo HH, Kim K, et al. Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin. Toxicol Sci 2014;138:446-556.
101. Kang S, Kim K, Noh JY, et al. Simvastatin induces the apoptosis of normal vascular smooth muscle through the disruption of actin integrity via the impairment of RhoA/Rac-1 activity. Thromb Haemost 2016;116:496-505.
102. Yandrapalli S, Malik A, Guber K, et al. Statins and the potential for higher diabetes mellitus risk. Expert Rev Clin Pharmacol 2019;12:825-30.
